Behavioral Pharmacology of the Cholinergic System
Published on 30. August 2020
Book
Hardback
X, 245 pages
978-3-030-56012-6 (ISBN)
Description
The molecular genetics of the cholinergic system including both muscarinic and nicotinic acetylcholine receptors, cholinesterases, acetylcholine synthesis and release have provided significant insights into potential targeting for pharmacological intervention. Cholinergic drugs are being used or evaluated for the treatment of diseases. Thus, this volume aims to broaden our understanding of the current state of cholinergic mechanisms to enable implementation of novel approaches for the development of more effective treatments.
More details
Series
Edition
2020 ed.
Language
English
Place of publication
Cham
Switzerland
Publishing group
Springer International Publishing
Target group
Professional and scholarly
Illustrations
1 s/w Abbildung
X, 245 p. 1 illus.
Dimensions
Height: 241 mm
Width: 160 mm
Thickness: 20 mm
Weight
553 gr
ISBN-13
978-3-030-56012-6 (9783030560126)
DOI
10.1007/978-3-030-56013-3
Schweitzer Classification
Other editions
Additional editions
Mohammed Shoaib | Tanya L. Wallace
Behavioral Pharmacology of the Cholinergic System
Book
08/2021
Springer
€181.89
Shipment within 7-9 days
Mohammed Shoaib | Tanya L. Wallace
Behavioral Pharmacology of the Cholinergic System
E-Book
08/2020
1st Edition
Springer
€171.19
Available for download
Content
A Review of the Cholinergic System and Therapeutic Approachesto Treat Brain Disorders.- Acetylcholine and Spontaneous Recognition Memory in Rodentsand Primates.- Endogenous Acetylcholine and Its Modulation of Cortical Microcircuitsto Enhance Cognition.- Cholinergic Signaling Dynamics and Cognitive Control of Attention.- Involvement of Nicotinic Receptors in Working Memory Function.- Nicotinic Receptors Underlying Nicotine Dependence: Evidence fromTransgenic Mouse Models.- Cholinergic Receptors and Addiction.- Behavioral and Molecular Basis of Cholinergic Modulation of Pain: Focus on Nicotinic Acetylcholine Receptors.- An Evolving Therapeutic Rationale for Targeting the a7 Nicotinic Acetylcholine Receptor in Autism Spectrum Disorder.- Activators of a7 nAChR as Potential Therapeutics for Cognitive Impairment.